Fracture risk following intermission of osteoporosis therapy

被引：0

作者：

E.M. Dennison

C. Cooper

J.A. Kanis

O. Bruyère

S. Silverman

E. McCloskey

B. Abrahamsen

D. Prieto-Alhambra

S. Ferrari

机构：

[1] University of Southampton,MRC Lifecourse Epidemiology Unit

[2] University of Oxford,Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences

[3] University of Sheffield,Centre for Metabolic Bone Diseases, University of Sheffield Medical School

[4] Australian Catholic University,Mary McKillop Health Institute

[5] University of Liège,World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Ageing, Department of Public Health, Epidemiology and Health Economics

[6] Cedars-Sinai/UCLA Medical Center and OMC Clinical Research Center,Academic Unit of Bone Metabolism, Department of Oncology and Metabolism, The Mellanby Centre For Bone Research

[7] University of Sheffield,Department of Medicine

[8] Holbaek Hospital,OPEN, Institute of Clinical Research

[9] University of Southern Denmark,Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences

[10] University of Oxford,GREMPAL Research Group, Idiap Jordi Gol and CIBERFes

[11] Universitat Autonoma de Barcelona and Instituto de Salud Carlos III,Division of Bone Disease, Faculty of Medicine

[12] Geneva University Hospital,undefined

来源：

Osteoporosis International | 2019年 / 30卷

关键词：

Atypical fracture; Bisphosphonates; Denosumab; Drug holiday;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1733 / 1743

页数：10

共 50 条

[41] Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis
Morris, Gloria J.
Mitchell, Edith P.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2007, 99 (01) : 35 - 45
[42] Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
Chesnut, CH
Skag, A
Christiansen, C
Recker, R
Stakkestad, JA
Hoiseth, A
Felsenberg, D
Huss, H
Gilbride, J
Schimmer, RC
Delmas, PD
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) : 1241 - 1249
[43] Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis
C. Beaudoin
S. Jean
L. Bessette
L.-G. Ste-Marie
L. Moore
J. P. Brown
Osteoporosis International, 2016, 27 : 2835 - 2844
[44] Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis
Beaudoin, C.
Jean, S.
Bessette, L.
Ste-Marie, L. -G.
Moore, L.
Brown, J. P.
OSTEOPOROSIS INTERNATIONAL, 2016, 27 (09) : 2835 - 2844
[45] Safety issues with bisphosphonate therapy for osteoporosis
Suresh, Ernest
Pazianas, Michael
Abrahamsen, Bo
RHEUMATOLOGY, 2014, 53 (01) : 19 - 31
[46] Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS
Tsourdi, Elena
Zillikens, M. Carola
Meier, Christian
Body, Jean-Jacques
Rodriguez, Elena Gonzalez
Anastasilakis, Athanasios D.
Abrahamsen, Bo
McCloskey, Eugene
Hofbauer, Lorenz C.
Guanabens, Nuria
Obermayer-Pietsch, Barbara
Ralston, Stuart H.
Eastell, Richard
Pepe, Jessica
Palermo, Andrea
Langdahl, Bente
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (01) : 264 - 281
[47] Analysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis
Miller, P
SOUTHERN MEDICAL JOURNAL, 2003, 96 (05) : 478 - 485
[48] My mother was saved from hip fracture by treatment for osteoporosis, but will I be?-Implications on risk estimates from successful osteoporosis treatment
Rosengren, B. E.
Karlsson, M. K.
OSTEOPOROSIS INTERNATIONAL, 2013, 24 (02) : 739 - 739
[49] Bone loss and fracture risk associated with cancer therapy
Guise, Theresa A.
ONCOLOGIST, 2006, 11 (10) : 1121 - 1131
[50] My mother was saved from hip fracture by treatment for osteoporosis, but will I be?—Implications on risk estimates from successful osteoporosis treatment
B. E. Rosengren
M. K. Karlsson
Osteoporosis International, 2013, 24 : 739 - 739

← 1 2 3 4 5 →